Dose proportional exposure was achieved across both arms.
The half-life of revumenib in Arm A (without strong CYP3A4 inhibitors) was approximately 3 h at the cycle 1 day 8 assessment of the 276-mg q12h dose level and was approximately 8 h at the same assessment in Arm B (with a strong CYP3A4 inhibitor) at the 163-mg q12h dose level. Data represent mean ± SD. Data cutoff date for pharmacokinetic analysis was July 11, 2022. CYP3A4, cytochrome P450 3A4; q12h, every 12 h; SD, standard deviation.
